Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biofield to market ValiRx cancer diagnostics worldwide

This article was originally published in Clinica

Executive Summary

Cancer therapeutics firm ValiRx (London, UK) is set to take its diagnostic tests to the worldwide market, through the partnership of its Belgium-based cancer diagnostics subsidiary ValiBio with medtech company Biofield. Philadelphia, Pennsylvania-based Biofield has gained exclusive worldwide distribution rights to ValiBio’s human papilloma virus (HPV) diagnostic test for cervical cancer, and non-exclusive global rights (excluding Belgium) to its Hypergenomics and Nucleosomics cancer diagnostic products. As part of the agreement, Biofield has bought a 10% stake in ValiBio for €600,000 ($819,000) in cash and has an option to secure an additional 15% holding. According to ValiRx, the global market for HPV testing is currently worth around $250m and is predicted to reach $1bn should it replace conventional cervical cancer testing methods.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042244

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel